Literature DB >> 6469353

Antibody in host defense against mouse pneumonitis agent (murine Chlamydia trachomatis).

D M Williams, J Schachter, M H Weiner, B Grubbs.   

Abstract

In a murine model of chlamydial pneumonia employing murine Chlamydia trachomatis, immune serum given intranasally delayed death in nude (nu/nu) mice and prevented death in nu/+ mice. Serum-derived immunoglobulin G and A fractions and immune lavage fluid fractions containing immunoglobulins G and A were effective in producing protection when used to opsonize the murine C. trachomatis inoculum. In hyperclean mice (previously made germfree and then colonized with a limited flora nonpathogenic to mice) antibody given intravenously was ineffective. The effects of antibody and nonspecific stimulation of cell-mediated immunity (after previous infection with Histoplasma capsulatum) were additive in increasing host resistance to murine C. trachomatis.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6469353      PMCID: PMC263348          DOI: 10.1128/iai.45.3.674-678.1984

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  18 in total

1.  Isolation of pure IgG1, IgG2a and IgG2b immunoglobulins from mouse serum using protein A-sepharose.

Authors:  P L Ey; S J Prowse; C R Jenkin
Journal:  Immunochemistry       Date:  1978-07

Review 2.  Nude mice in immunology.

Authors:  B Kindred
Journal:  Prog Allergy       Date:  1979

3.  Immunity to chlamydial infections of the eye. I. The role of circulatory and secretory antibodies in resistance to reinfection with guinea pig inclusion conjunctivitis.

Authors:  E S Murray; L T Charbonnet; A B MacDonald
Journal:  J Immunol       Date:  1973-06       Impact factor: 5.422

4.  Immunity to chlamydial infections of the eye. VI. Homologous neutralization of trachoma infectivity for the owl monkey conjuctivae by eye secretions from humans with trachoma.

Authors:  R L Nichols; R E Oertley; E C Fraser; A B MacDonald; D E McComb
Journal:  J Infect Dis       Date:  1973-04       Impact factor: 5.226

5.  Immunologic relationship between genital TRIC, lymphogranuloma venereum, and related organisms in a new microtiter indirect immunofluorescence test.

Authors:  S P Wang; J T Grayston
Journal:  Am J Ophthalmol       Date:  1970-09       Impact factor: 5.258

6.  Growth of Chlamydia psittaci in macrophages.

Authors:  P B Wyrick; E A Brownridge
Journal:  Infect Immun       Date:  1978-03       Impact factor: 3.441

7.  Effect of alveolar macrophages on Toxoplasma gondii.

Authors:  F W Ryning; J S Remington
Journal:  Infect Immun       Date:  1977-12       Impact factor: 3.441

8.  Antibody-dependent cell-mediated antibacterial activity of intestinal lymphocytes with secretory IgA.

Authors:  A Tagliabue; L Nencioni; L Villa; D F Keren; G H Lowell; D Boraschi
Journal:  Nature       Date:  1983 Nov 10-16       Impact factor: 49.962

9.  Correlation of host immune response with quantitative recovery of Chlamydia trachomatis from the human endocervix.

Authors:  R C Brunham; C C Kuo; L Cles; K K Holmes
Journal:  Infect Immun       Date:  1983-03       Impact factor: 3.441

10.  Interaction of Chlamydia psittaci with mouse peritoneal macrophages.

Authors:  P B Wyrick; E A Brownridge; B E Ivins
Journal:  Infect Immun       Date:  1978-03       Impact factor: 3.441

View more
  18 in total

1.  T lymphocyte immunity in host defence against Chlamydia trachomatis and its implication for vaccine development.

Authors:  X Yang; R Brunham
Journal:  Can J Infect Dis       Date:  1998-03

2.  Native properdin binds to Chlamydia pneumoniae and promotes complement activation.

Authors:  Claudio Cortes; V P Ferreira; Michael K Pangburn
Journal:  Infect Immun       Date:  2010-12-06       Impact factor: 3.441

3.  Early complement components enhance neutralization of Chlamydia trachomatis infectivity by human sera.

Authors:  J S Lin; L L Yan; Y Ho; P A Rice
Journal:  Infect Immun       Date:  1992-06       Impact factor: 3.441

4.  Protection of wild-type and severe combined immunodeficiency mice against an intranasal challenge by passive immunization with monoclonal antibodies to the Chlamydia trachomatis mouse pneumonitis major outer membrane protein.

Authors:  Sukumar Pal; Jose Bravo; Ellena M Peterson; Luis M de la Maza
Journal:  Infect Immun       Date:  2008-09-22       Impact factor: 3.441

5.  Complement factor C5 but not C3 contributes significantly to hydrosalpinx development in mice infected with Chlamydia muridarum.

Authors:  Zhangsheng Yang; Turner Conrad; Zhou Zhou; Jianlin Chen; Pavel Dutow; Andreas Klos; Guangming Zhong
Journal:  Infect Immun       Date:  2014-05-19       Impact factor: 3.441

6.  Divergent outcomes following transcytosis of IgG targeting intracellular and extracellular chlamydial antigens.

Authors:  Charles W Armitage; Connor P O'Meara; Marina C G Harvie; Peter Timms; Richard S Blumberg; Kenneth W Beagley
Journal:  Immunol Cell Biol       Date:  2014-01-21       Impact factor: 5.126

7.  Humoral and cellular immunity in secondary infection due to murine Chlamydia trachomatis.

Authors:  D M Williams; B G Grubbs; E Pack; K Kelly; R G Rank
Journal:  Infect Immun       Date:  1997-07       Impact factor: 3.441

8.  Role of CD8 T cells in primary Chlamydia infection.

Authors:  D M Magee; D M Williams; J G Smith; C A Bleicker; B G Grubbs; J Schachter; R G Rank
Journal:  Infect Immun       Date:  1995-02       Impact factor: 3.441

9.  Protective efficacy of major outer membrane protein-specific immunoglobulin A (IgA) and IgG monoclonal antibodies in a murine model of Chlamydia trachomatis genital tract infection.

Authors:  T W Cotter; Q Meng; Z L Shen; Y X Zhang; H Su; H D Caldwell
Journal:  Infect Immun       Date:  1995-12       Impact factor: 3.441

10.  Gene knockout mice establish a primary protective role for major histocompatibility complex class II-restricted responses in Chlamydia trachomatis genital tract infection.

Authors:  R P Morrison; K Feilzer; D B Tumas
Journal:  Infect Immun       Date:  1995-12       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.